Osborne Clarke advised LAVA Therapeutics on the deal. LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Paolo Bossi
…
This content is for Standard 1 Year members only. LoginJoin Now